MARKET

SCYX

SCYX

SCYNEXIS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.13
-0.45
-5.24%
After Hours: 8.30 +0.17 +2.09% 18:24 03/05 EST
OPEN
8.66
PREV CLOSE
8.58
HIGH
8.66
LOW
7.35
VOLUME
488.87K
TURNOVER
--
52 WEEK HIGH
10.50
52 WEEK LOW
4.201
MARKET CAP
155.59M
P/E (TTM)
-2.3362
1D
5D
1M
3M
1Y
5Y
SCYNEXIS (SCYX) Receives a Buy from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on SCYNEXIS (SCYX), with a price target of $22.00. The company's
SmarterAnalyst · 3d ago
Anti-fungal Drugs Market Size with Global Growth 2021: Top Countries Data with Business Sales Revenue, Opportunities, Industry Share, Drivers, and Risk Factor by Forecast Analysis 2024
Mar 03, 2021 (The Expresswire) -- Global “Anti-fungal Drugs Market” trend report covers vital factors about the marketplace, profitability, competitive...
The Express Wire · 4d ago
SCYNEXIS (SCYX) Gets a Buy Rating from Ladenburg Thalmann & Co.
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on SCYNEXIS (SCYX), with a price target of $25.00.
SmarterAnalyst · 4d ago
Sector Update: Health Care
MT Newswires · 5d ago
BRIEF-Scynexis Announces Positive Results From Interim Analyses Of Ongoing Phase 3 Studies (Furi And Cares), Demonstrating Oral Ibrexafungerp's Ability To Treat Severe Fungal Infections In The Hospital Setting
reuters.com · 5d ago
Scynexis' Drug Candidate Shows Positive Interim Results in Treating Fungal Infections
MT Newswires · 5d ago
Scynexis shares up 5% on positive ibrexafungerp data in fungal infections
Scynexis (SCYX) perks up 6% premarket on positive results from the interim efficacy analysis of Phase 3 FURI study and Phase 3 CARES study. In FURI study, antifungal activity was consistently positive
Seekingalpha · 5d ago
SCYNEXIS Announces Results From Interim Analyses Of Ongoing Phase 3 Studies Of Ibrexafungerp; Says Results Show 'positive clinical activity' Of Oral Ibrexafungerp In Patients With Fungal Infections
Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including
Benzinga · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SCYX. Analyze the recent business situations of SCYNEXIS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SCYX stock price target is 30.57 with a high estimate of 45.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 19.10M
% Owned: 99.78%
Shares Outstanding: 19.14M
TypeInstitutionsShares
Increased
15
1.73M
New
15
5.43M
Decreased
6
63.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Pamela Kirby
President/Chief Executive Officer/Director
Marco Taglietti
Chief Financial Officer
Eric Francois
Vice President/Director of Sales/Director of Marketing
Jim Maffezzoli
Vice President
Nkechi Azie
General Counsel
Scott Sukenick
Other
David Angulo
Director
Armando Anido
Director
Laurent Arthaud
Director
Steven Gilman
Director
Ann Hanham
Director
David Hastings
Director
Patrick Langlois
Director
Clarence Machado
Director
Guy Macdonald
Director
Jean-Yves Nothias
Director
Philippe Tinmouth
No Data
  • All
  • Financials
  • Insiders
More
About SCYX
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.